Alisporivir (ALV) plus peginterferon/ribavirin (PR) achieves high SVR12 rates among null responders, IL28BCT/TT and cirrhotic HCVG1 patients (fundamental study interim analysis)

Authors
Category Primary study
JournalJournal of Hepatology
Year 2013
This article has no abstract
Epistemonikos ID: 1660fad1cc43a14ea3e23bfdde9da6ddd7b50faa
First added on: Feb 05, 2025